We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.20
Bid: 5.52
Ask: 7.00
Change: 0.08 (1.31%)
Spread: 1.48 (26.812%)
Open: 6.20
High: 6.20
Low: 6.20
Prev. Close: 6.12
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

finnCap Interim Profit More Than Doubles; Chair To Step Down

Wed, 18th Nov 2020 13:59

(Alliance News) - finnCap Group PLC on Wednesday said profit in the first half of its financial year more than doubled amid increased equity fundraising from clients.

Shares in finnCap were up 12% at 21.80 pence in London in afternoon trading.

The London-based stockbroker reported a GBP3.6 million pretax profit for the six months ended September 30, more than twice the GBP1.4 million profit reported in the prior year.

This came as revenue jumped 44% to GBP20.5 million from GBP14.2 million.

finnCap explained: "Against our initial expectations, activity in our markets in H1 has been strong, with increased equity fundraisings to support our clients' financial needs and investment in strong business cases. We have also benefited from on-going long-term investment in building leading expertise in the healthcare, biotech and tech sectors where there has been significant corporate activity.

"As a result, revenue generation in H1 has proven to be stronger than we expected and, with cost actions outlined above, we have therefore delivered materially higher profits and cashflow than in H1 last year."

The firm raised more than GBP300 million across 15 equity fundraisings for listed clients, plus 2 initial public offerings. It also advised on 4 completed takeovers and public company advisory roles worth GBP212 million total.

finnCap said its financial third quarter has started well with the completion of the Fonix Mobile PLC IPO, which raised GBP45 million, as well as a GBP87 million placing and open offer for Synairgen PLC. It is expecting "a good result" for financial 20201, which ends March 31, "well ahead of the prior year". finnCap also expects its disposal of a 70% holding in PrimaryBid Ltd, for approximately GBP700,000, to complete in early 2021.

Jon Moulton, finnCap's chief executive officer, it to retire at the end of December, succeeded by Robert Lister. Lister, who joins finnCap January 1, "spent 25 years in investment banking first with Barclays de Zoete Wedd where he started as a graduate in 1983 and rose to become head of European Equities in 1998 and then at Dresdner Kleinwort Benson where he was global head of Equities."

Howard Leigh will step down from the board, becoming senior partner of newly integrated Corporate Finance (UK) Ltd.

Chief Executive Sam Smith said: "Our strategy of developing a full suite of products for growth companies - which, we believe, differentiates us from our peers - is delivering incremental revenue. Having completed the integration of Cavendish, we are now moving into a key phase of our strategy - carefully seeking bolt on acquisitions in adjacent sectors which align with our culture and further our vision of building a more broadly-based group, focused on servicing growing companies' needs.

"The uncertain operating environment means we must remain cautious, however, Q3 has started well, with the completion of the IPO of Fonix Mobile and a further large fund raising for Synairgen and our pipeline of deals remains good."

The company declared a 0.5 pence per share interim dividend, having ceased dividend payments in financial 2020.

Additionally, finnCap noted its chief financial officer, Richard Snow, bought 95,364 shares at 22.65 pence each, worth GBP21,600, on Wednesday. Snow now is interested in 328,697 shares, a 0.2% stake.

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
28 May 2020 14:49

UK TRADING UPDATE SUMMARY: PureTech, N4, Synairgen Advance Covid Work

UK TRADING UPDATE SUMMARY: PureTech, N4, Synairgen Advance Covid Work

Read more
26 May 2020 13:55

Synairgen Loss Widens; Progressing On SNG001 Study For Covid-19

Synairgen Loss Widens; Progressing On SNG001 Study For Covid-19

Read more
31 Mar 2020 12:21

UK TRADING UPDATE SUMMARY: Synairgen Starts Covid-19 Treatment Trial

UK TRADING UPDATE SUMMARY: Synairgen Starts Covid-19 Treatment Trial

Read more
29 Mar 2020 21:00

Sunday share tips: Synairgen, Hollywood Bowl

(Sharecast News) - The Sunday Times's Sabah Meddings recommends buying shares of Synairgen arguing that the Covid-19 pandemic may have given the firm a new lease on life.

Read more
29 Mar 2020 20:57

Sunday newspaper round-up: Restrictions, Unemployment, Blood plasma

(Sharecast News) - "Life in Britain will not return to normal for six months, England's deputy chief medical officer has warned, as ministers begin preparing the public for an extended period of lockdown. At the government's daily press conference, Jenny Harries said that strict social distancing rules may have to be in place for between two and three months. But she added that it would be a further three months before all restrictions were lifted, and even then there were likely to be "bumps" as new clusters of cases of coronavirus were identified." - Sunday Times

Read more
26 Mar 2020 14:26

UPDATE: Synairgen Successfully Raises Cash For Covid-19 Trials

UPDATE: Synairgen Successfully Raises Cash For Covid-19 Trials

Read more
26 Mar 2020 06:58

Synairgen Raises Cash To Go Towards Covid-19 Drug Trial

Synairgen Raises Cash To Go Towards Covid-19 Drug Trial

Read more
18 Mar 2020 18:42

Britain's Synairgen gets green light for coronavirus drug trial

By Paul SandleLONDON, March 18 (Reuters) - British pharmaceutical company Synairgen said on Wednesday it had the go-ahead to test a drug that could boost the lung function of patients with coronavirus, potentially assisting in the global fight aga...

Read more
18 Mar 2020 16:59

Synairgen Gets Expedited UK Approval To Trial SNG001 For Covid-19

Synairgen Gets Expedited UK Approval To Trial SNG001 For Covid-19

Read more
18 Mar 2020 11:17

Synairgen to begin trial of potential Covid-19 therapy

(Sharecast News) - Respiratory drug discovery company Synairgen has received expedited approvals from the Medicines and Healthcare Products Regulatory Agency (MHRA) and Health Research Authority (HRA) to conduct a trial of 'SNG001', an inhaled formulation of interferon-beta-1a, in Covid-19 coronavirus patients, to potentially assist with the global virus pandemic.

Read more
1 Oct 2019 13:42

Synairgen Interim Loss Deepens On Costs As Progresses Clinical Trials

Synairgen Interim Loss Deepens On Costs As Progresses Clinical Trials

Read more
27 Sep 2019 13:32

Synairgen Expects Positive Outcome From Second Part Of SNG001 Study

Synairgen Expects Positive Outcome From Second Part Of SNG001 Study

Read more
24 Jul 2019 12:58

Synairgen Encouraged By Findings So Far In Interferon Beta COPD Study

(Alliance News) - Synairgen PLC on Wednesday said a phase two trial in its inhaled interferon beta programme has found cold and flu infections worsen symptoms for chronic obstructive pulmonary in

Read more
9 Jul 2019 09:26

CORRECT (Jul 8): Woodford Transfers Company Stakes After Omnis Departs

(Correcting that Woodford Investment Management transferred a number of stakes following Omnis's decision. It did not sell these stakes, as was originally reported.)(Alliance News) - of

Read more
18 Apr 2019 11:52

Synairgen Non-Executive Director Paul Clegg To Retire In June

LONDON (Alliance News) - Synairgen PLC on Thursday said Non-Executive Director Paul Clegg will retire from the company's board after the company's annual general meeting on June Buchanan,

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.